Olon Group is a global leader in the development and production of active pharmaceutical ingredients (APIs) for CDMO and Generics. It provides an integrated package of chemical synthesis and biological processing services which clients can use to manage their drug manufacturing projects fully compliant with regulations.
We rely on a global network of 11 manufacturing site and 7 R&D departments across the globe, on several decades of experience in supporting pharmaceutical, biotech, food, chemical and bio-industrial companies.
Thanks to 2.300 employees and 300 highly experienced and qualified people in R&D team, we are a highly reliable partner.
In Olon, expertise and competence are combined with great flexibility at different levels, remarkably in the field of microbial fermentation, always considering human safety and environmental security.
Through chemical synthesis, microbial biomanufacturing or a semi-synthesis approach, we offer, under GMP, dedicated solutions for the development and manufacturing of NCEs, advanced intermediates, building blocks, enzymes & proteins, peptides of rDNA origin and high potency drugs.
We guarantee customer support from the R&D lab up to full-scale commercial manufacturing and strong regulatory support. Our experience and global footprint allow us to follow the entire process in house, with a single point of contact for the customer and complete accountability.
During product development and technology transfer, our partners are supported by a dedicated team; it is made up of a project management accountable, which plans and tracks all activities, resolves any conflict of resources, solves critical issues, and communicates news and updates, and a technical team, which provides regular updates on the project status (Reports – TCs), communicates directly with the customer for technical topics, and supports the regulatory strategy.
Olon is a leading international Generic API supplier. We have in place a global business model that allows us to be a competitive and cost-effective API supplier to the Generics industry. We manufacture products via chemical as well as biological synthesis, relying on extended internal technical expertise while meeting
the highest standards of quality and reliability. We have carried on since time a business continuity program to diversify our sources for all our key raw materials and reinforce the risk mitigation plan. Additionally, Olon’s facility footprint is truly global, with bases in the United States, Europe, China, and India.
With a portfolio of 300 Generic APIs, we offer one of the most extensive track records in the industry and we manage more than 450 Drug Master Files.
Olon has diversified and backed investments across several lines and multiple facilities to be able to manage various high-containment molecules at different scales